Jeffrey S. Chamberlain, PhD, on Regulating DMD Gene Therapy Clinical Trials
March 9th 2023The professor and director of the Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center at University of Washington School of Medicine discussed working with the FDA toward a first disease-modifying therapy approval in Duchenne.
Jeffrey S. Chamberlain, PhD, on Reviewing Micro-Dystrophin as a Surrogate Endpoint in DMD
February 11th 2023The professor and director of the Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center at University of Washington School of Medicine discussed the paper he recently coauthored.